Skip to Content

Challenge Grants

Published on January 16, 2025

Time to read: 2 minutes

This program is currently closed. The details below reflect the previous call and are for general information purposes only.

Sponsor’s Website

Visit the Canadian Cancer Society website for more information on the Challenge Grants.

Internal Contact

Katie Harriman: katie.harriman@carleton.ca

Deadlines

DeadlineDate
Abstract registration (mandatory)October 8, 2025 by 5 p.m. (EST)
Relevance review resultsOctober 31, 2025
Internal cuResearch Approval FormJanuary 21, 2026
Submission of application to the Canadian Cancer SocietyJanuary 28, 2026 by 5 p.m. (EST)

Overview

The Challenge Grants support cancer research projects across the cancer continuum and across disciplines, with an ultimate goal of solving a problem (i.e., a “challenge”) in cancer that is meaningful to people affected by or at risk of cancer. Applications from the four pillars of health research are welcome: (i) biomedical, (ii) clinical, (iii) health services and (iv) social, cultural, environmental and population health.

Value and Duration

Up to $175,000 per year for up to three years (15% equipment budget).

Eligibility

Challenges should align with the Society’s research goals (prevent, detect, care, champion). Applicants must clearly articulate the relevance to people affected by or at risk of cancer, as well as describe the anticipated contribution of their proposed project towards solving the identified challenge.

Research must include people affected by or at risk of cancer as an integral part of the team.

Indirect costs are not eligible.

Special Considerations

Several special funding calls to support high-quality research are included within the broader Challenge Grant competition.

Submitting Your Application

  1. Submit an internal Approval Form through our central awards management database cuResearch. Consult the user’s manual for guidance.
  2. Submit an external application to the Canadian Cancer Society by following their submission guidelines.